Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Allogene Therapeutics Inc is a biotechnology business based in the US. Allogene Therapeutics shares (ALLO) are listed on the NASDAQ and all prices are listed in US Dollars. Allogene Therapeutics employs 285 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$15.65|
|52-week range||$13.01 - $39.12|
|50-day moving average||$22.07|
|200-day moving average||$25.09|
|Wall St. target price||$37.19|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.82|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-18)||-0.51%|
|1 month (2021-09-24)||-39.01%|
|3 months (2021-07-27)||-27.58%|
|6 months (2021-04-27)||-56.28%|
|1 year (2020-10-26)||-56.24%|
|2 years (2019-10-25)||-46.28%|
|3 years (2018-10-26)||23|
|5 years (2016-10-23)||N/A|
|Revenue TTM||$38.4 million|
|Gross profit TTM||$0|
|Return on assets TTM||-12.66%|
|Return on equity TTM||-21.83%|
|Market capitalisation||$2.2 billion|
TTM: trailing 12 months
There are currently 8.0 million Allogene Therapeutics shares held short by investors – that's known as Allogene Therapeutics's "short interest". This figure is 1.7% up from 7.9 million last month.
There are a few different ways that this level of interest in shorting Allogene Therapeutics shares can be evaluated.
Allogene Therapeutics's "short interest ratio" (SIR) is the quantity of Allogene Therapeutics shares currently shorted divided by the average quantity of Allogene Therapeutics shares traded daily (recently around 670734.28571429). Allogene Therapeutics's SIR currently stands at 11.9. In other words for every 100,000 Allogene Therapeutics shares traded daily on the market, roughly 11900 shares are currently held short.
However Allogene Therapeutics's short interest can also be evaluated against the total number of Allogene Therapeutics shares, or, against the total number of tradable Allogene Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Allogene Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Allogene Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.0915% of the tradable shares (for every 100,000 tradable Allogene Therapeutics shares, roughly 92 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Allogene Therapeutics.
Find out more about how you can short Allogene Therapeutics stock.
We're not expecting Allogene Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Allogene Therapeutics's shares have ranged in value from as little as $13.01 up to $39.12. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Allogene Therapeutics's is 0.9967. This would suggest that Allogene Therapeutics's shares are less volatile than average (for this exchange).
Allogene Therapeutics, Inc. , a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc. ; Servier; Cellectis S.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.